Texas Oncology’s virtual care navigation pilot supported 740 patients on oral oncolytics across 11 community sites, offering ...

Theodore Wagener, PhD, discusses psychedelics beyond depression in cancer, including neuropathy and chemo brain, and why he ...

Pollack, MD, and participants discussed 2 investigational agents for recurrent diffuse tenosynovial giant cell tumor and how ...

The FDA has allowed the launch of a phase 2 study of MT027, an allogeneic chimeric antigen receptor (CAR) T-cell therapy ...

Otero, MD, discusses how T-cell–engaging therapies are aiming to meaningfully impact or negate the disease course of ...

Alicia Morgans, MD, explains how the ARACOG trial showed higher cognitive decline with enzalutamide vs darolutamide in ...

Targeted Oncology™ is a leading omnichannel resource for community oncologists, offering innovative learning and peer interaction through print and digital platforms. Our custom programs meet your ...

Targeted Therapies in Oncology provides evidence-based news and updates on the most current advances in therapeutics, biomarkers, pathways, biomarkers, molecular profiling, and diagnostic testing with ...

The Journal of Targeted Therapies in Cancer | Targeted Publications | Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Explore why some patients with multiple myeloma miss stem cell transplant, spotlighting age, race and socioeconomic barriers, ...

Community oncologists play an important role in expanding access to clinical trials. Patel discusses the value of offering ...

Dr. Jason Mouabbi presents a 59-year-old postmenopausal woman with PIK3CA-mutated HR-positive/HER2-negative advanced breast ...